Gastrointestinal infiltration secondary to extramedullary anaplastic plasmacytoma. A rare cause of intestinal subocclusion and upper gastrointestinal bleeding.

Extramedullary plasmacytoma is rare, it can appear alone or associated with multiple myeloma, representing an extramedullary progression of the disease. We present the case of a 62-year-old woman diagnosed with multiple myeloma who, being in complete remission began to experience abdominal pain and nausea. A rare cause of intestinal subocclusion and upper gastrointestinal bleeding.

Primary gastric rhabdomyosarcoma. A rare cause of an upper gastrointestinal bleeding.

Adenocarcinoma accounts for 90% of malignant gastric tumours. Lymphomas, gastrointestinal stromal tumours (GIST) and other less frequent tumours account for 10%. However, rhabdomyosarcoma (RMS) remains a rare cause within the broad differential diagnosis of gastric lesions.

Management of cytomegalovirus reactivation in patient with immunotherapy-induced gastritis.

We present the case of a 52-year-old woman diagnosed with stage IV clear cell renal cell carcinoma who received combination of surgery and systemic therapy with nivolumab (anti-PD1) and ipilimumab (anti-CTLA-4). During treatment, patient presented oral intolerance, vomiting and abdominal pain. Computed tomography (CT) and gastroscopy (EGD) were performed, identifying findings suggestive of severe gastro-duodenitis with friability and diffuse oedema of the mucosa and deep ulcers.

Long-term augmentation therapy with alpha-1 antitrypsin in an MZ-AAT severe persistent asthma.

A young Caucasian female with severe bronchial asthma and Alpha1-antitrypsin (AAT) deficiency, MZ phenotype, experienced a quick and severe limitation of her physical capacity, which negatively affected her psychological state and social life, though she was under a strong antiasthmatic treatment. Given her declining health status and the significant chronic corticoid administration-related side-effects (including high reduction of muscle mass and bone density), a clinical trial with commercial intravenous AAT was proposed by the patient's doctors, and accepted by the Spanish Ministry of Health, although it this therapy was not approved for MZ phenotypes yet. This new therapy quickly stopped lung function decline rate, dramatically reduced the number of hospital admissions of the patient, suppressed the oral administration of prednisone, reversed the corticosteroid-related health adverse effects, significantly improving her quality of life.

Anti-GBM and anti-MPO antibodies coexist in a case of pulmonary renal syndrome.

The case of a 12-year-old boy with pulmonary renal syndrome is described. Antimyeloperoxidase (anti-MPO) and antiglomerular basement membrane (anti-GBM) antibodies were positive. The clinical course and immunosuppressive therapy are discussed.